MedPath

BMS-813160

Generic Name
BMS-813160
Drug Type
Small Molecule
Chemical Formula
C25H40N8O2
CAS Number
1286279-29-5
Unique Ingredient Identifier
83U7957287
Background

BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).

Clinical Trials
Related News

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Phase 2
Active, not recruiting
Conditions
Non-small Cell Lung Cancer
Hepatocellular Carcinoma
Interventions
First Posted Date
2019-10-10
Last Posted Date
2025-01-17
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
48
Registration Number
NCT04123379
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1
Completed
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Procedure: Biopsy
Procedure: Peripheral blood
First Posted Date
2018-04-12
Last Posted Date
2025-03-25
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
40
Registration Number
NCT03496662
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Phase 1
Completed
Conditions
Pancreatic Cancer
Colorectal Cancer
Interventions
Biological: Nivolumab
First Posted Date
2017-06-14
Last Posted Date
2023-07-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
332
Registration Number
NCT03184870
Locations
🇺🇸

Local Institution - 0004, Hackensack, New Jersey, United States

🇺🇸

Local Institution - 0033, Boston, Massachusetts, United States

🇺🇸

Local Institution - 0027, Rochester, Minnesota, United States

and more 37 locations

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Phase 2
Completed
Conditions
Advanced Cancer
Interventions
Biological: Nivolumab
Biological: Ipilimumab
Biological: Relatlimab
First Posted Date
2016-12-19
Last Posted Date
2022-12-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
182
Registration Number
NCT02996110
Locations
🇦🇹

Local Institution - 0044, Linz, Oberösterreich, Austria

🇺🇸

Local Institution - 0043, Charlotte, North Carolina, United States

🇺🇸

Local Institution - 0007, Baltimore, Maryland, United States

and more 27 locations

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Phase 2
Terminated
Conditions
Diabetic Kidney Disease
Interventions
Drug: Placebo matching with BMS-813160
First Posted Date
2012-12-19
Last Posted Date
2019-07-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
319
Registration Number
NCT01752985
Locations
🇺🇸

Academic Medical Research Institute, Los Angeles, California, United States

🇨🇦

Recherche Gcp Research, Montreal, Quebec, Canada

🇨🇦

Eastern Health Sciences Center, St. John's, Newfoundland and Labrador, Canada

and more 47 locations

Single Ascending Dose (BMS-813160) Study

Phase 1
Completed
Conditions
Accelerated Intimal Hyperplasia
Interventions
Drug: Placebo
First Posted Date
2010-01-14
Last Posted Date
2011-02-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
70
Registration Number
NCT01049165
Locations
🇺🇸

Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy